Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Reetta Vainionpää"'
Autor:
Arafat Siddiqui, Manuela Tumiati, Alia Joko, Jouko Sandholm, Pia Roering, Sofia Aakko, Reetta Vainionpää, Katja Kaipio, Kaisa Huhtinen, Liisa Kauppi, Johanna Tuomela, Sakari Hietanen
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Critical DNA repair pathways become deranged during cancer development. This vulnerability may be exploited with DNA-targeting chemotherapy. Topoisomerase II inhibitors induce double-strand breaks which, if not repaired, are detrimental to the cell.
Externí odkaz:
https://doaj.org/article/6a72803515b2449c90dd67582d36c593
Autor:
Terhi Jokilehto, Milja Kaare, Olli Carpén, Reetta Vainionpää, Jari Sundström, Ari Ristimäki, Minnamaija Lintunen, Arto Orpana, Pia Österlund, Raija Ristamäki, Annika Ålgars, Soili Kytölä
Publikováno v:
International Journal of Cancer. 140:922-929
Anti-EGFR antibodies are used for the treatment of RAS wild type metastatic colorectal cancer. We previously showed that EGFR gene copy number (GCN) predicts response to anti-EGFR therapy in KRAS exon 2 wild type metastatic colorectal cancer. The aim
Autor:
Leena Valanne, Reetta Vainionpää, Virve Pentikäinen, Sanna-Maria Kivivuori, Atte Karppinen, Jarno Satopää, Anna Raunio, Minna Oinas, Juha Hernesniemi, Olli Tynninen, Mikaela Porkholm, Tarja Salonen
Publikováno v:
Pediatric bloodcancer. 65(1)
Background Diffuse intrinsic pontine gliomas (DIPGs) have a dismal prognosis. Previously, diagnosis was based on a typical clinical presentation and magnetic resonance imaging findings. After the start of the era of biopsies, DIPGs bearing H3 K27 mut
Autor:
Annika, Ålgars, Jari, Sundström, Minnamaija, Lintunen, Terhi, Jokilehto, Soili, Kytölä, Milja, Kaare, Reetta, Vainionpää, Arto, Orpana, Pia, Österlund, Ari, Ristimäki, Olli, Carpen, Raija, Ristamäki
Publikováno v:
International journal of cancer. 140(4)
Anti-EGFR antibodies are used for the treatment of RAS wild type metastatic colorectal cancer. We previously showed that EGFR gene copy number (GCN) predicts response to anti-EGFR therapy in KRAS exon 2 wild type metastatic colorectal cancer. The aim